Oxford BioMedica Plc - Company Profile
Powered by 
All the data and insights you need on Oxford BioMedica Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Oxford BioMedica Plc Strategy Report
- Understand Oxford BioMedica Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Oxford BioMedica Plc (Oxford Biomedica) is a contract development and manufacturing services organization that specializes in cell and gene therapy. It provides LentiVector, a sector leading lentiviral vector delivery platform and adeno-associated virus (AAV) platform to various pharmaceutical and biotechnology companies. Based on this platform the company has also developed a portfolio of gene and cell therapy product candidates in ophthalmology, oncology, central nervous system (CNS), and other therapy areas. It has partnership and license agreement with other companies to develop potential gene and cell therapy products. The company has presence in different locations in the UK and in Boston, the US. Oxford BioMedica is headquartered in Oxford, the UK.
Headquarters
United Kingdom
Address
Windrush Court, Transport Way, Oxford, England, OX46LT
Website
www.oxb.com
Telephone
44 1865 783000
No of Employees
891
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OXB (LON)
Revenue (2021)
$172.5M
-2%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-306%
(2021 vs 2020)
Market Cap*
$252.1M
Net Profit Margin (2022)
XYZ
-310.1%
(2021 vs 2020)
* As of and is in US$
Oxford BioMedica Plc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Approved: | CDMO | Kymriah |
| Kymriah- Relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In March, the company updated its CDMO services activity. |
| 2024 | Acquisitions/Mergers/Takeovers | In January, the company acquired ABL Europe SAS from Institut Merieux. |
| 2023 | Contracts/Agreements | In September, the company entered into a multi-year license and supply agreement with Kyverna Therapeutics for the LentiVector platform. |
Competitor Comparison
| Key Parameters | Oxford BioMedica Plc | Almac Group Ltd | Alliance Pharma Plc | Agenus Inc | Silence Therapeutics Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United States of America | United Kingdom |
| City | Oxford | Craigavon | Chippenham | Lexington | London |
| State/Province | England | Northern Ireland | England | Massachusetts | England |
| No. of Employees | 891 | 6,600 | 249 | 533 | 116 |
| Entity Type | Public | Private | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frank Mathias | Chief Executive Officer; Director | Executive Board | 2023 | - |
| Stuart Paynter | Director; Chief Financial Officer | Executive Board | 2017 | - |
| Nick Page | Chief Operating Officer | Senior Management | 2019 | - |
| Matthew Treagus | Chief - Staff; Chief Information Officer | Senior Management | 2021 | - |
| Lisa James | Chief People Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward